Academic Journals Database
Disseminating quality controlled scientific knowledge

Modern pharmacotherapy of the stable angina: possibilities and prospects of nicorandil implementation

Author(s): Z.M. Sizova | E.V. Shikh | V.L. Zakharova | E.V. Smirnova

Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii
ISSN 1819-6446

Volume: 6;
Issue: 4;
Start page: 455;
Date: 2010;
Original page

Keywords: ischemic heart disease | stable angina | antianginal therapy | nicorandil.

Aim. To evaluate antianginal efficacy and safety of nicorandil for angina attack prevention and relief in patients with ischemic heart disease (IHD) and symptoms of stable angina class 2-3.Material and methods. 30 patients with stable angina class 2-3 (17 men, 13 women; aged 58.6±5.8 y.o.) were included into the study. All patients received amlodipine 10 mg QD within 2 weeks. For angina attack relief patients used nicorandil 10-20 mg and in case of its inefficacy — nitroglycerin. In 2 weeks all patients were randomized in 2 groups. Patients of the 1st group (n=15) received nicorandil 20 mg TID, patients of the 2nd group (n=15) — amlodipine 10 mg QD. The study duration was 3 months. The efficiency evaluation was based on the analysis of hemodynamic indicators (heart rate, blood pressure), bioelectric heart activity (electrocardiogram), velocity exercise tolerance test, ambulatory blood pressure monitoring indicators. The pain severity was defined with Borg's scale, and the quality of life — with General Health Questionnaire (GHQ-28). Therapy safety was evaluated in according to laboratory tests results.Results. Frequency of angina attacks reduced by 60% (р
Affiliate Program      Why do you need a reservation system?